Screener
Aquestive Therapeutics, Inc. AQST Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Personnel costs5 | 6,602 | 5,176 | 12,111 | 10,016 |
| Other6 | 5,287 | 4,009 | 8,834 | 15,285 |
| Total General and Administrative Expenses | 11,889 | 9,185 | 20,945 | 25,301 |
| Total Selling, General and Administrative Expenses | 14,063 | 12,705 | 25,040 | 31,777 |
| Total costs and expenses | 22,042 | 21,371 | 40,692 | 49,456 |
| Loss from operations | (8,223) | (11,368) | (12,427) | (30,733) |
| Other income/(expenses), net | (14,641) | (2,180) | (18,494) | (5,745) |
| Net loss before income taxes | (22,864) | (13,548) | (30,921) | (36,478) |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s business segments — SG&A?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — SG&A of $14.06M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — SG&A changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — SG&A increased by 10.7% year-over-year, from $12.71M to $14.06M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — SG&A?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — SG&A has grown at a 58.6% compound annual growth rate (CAGR), from $31.75M to $79.85M.
- What does business segments — SG&A mean?
- Represents the combined operating expenses related to selling, marketing, and general administrative support for the segment. This aggregate metric provides a comprehensive view of the non-production overhead required to operate the business unit. It is a key measure of the segment's overall operational efficiency and cost management performance.
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude